Tauklarify is a new PET imaging drug that lets doctors see tau tangles, a hallmark of Alzheimer's disease, inside a living brain. The FDA approved it on August 14, 2026, for adults with cognitive impairment — including mild cognitive impairment (MCI) — who are being evaluated for Alzheimer's, giving patients and clinicians a second tau-tracing option to weigh against existing tests, according to Lantheus's announcement. For someone with MCI, the practical question is not just whether a tau scan exists, but whether it is accurate enough, safe enough, and actually available to change a diagnosis or care plan. The sections below walk through what Tauklarify measures, how its accuracy compares with the one other approved tau tracer, what the scan involves physically, and what still stands between approval and a scan appointment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Tauklarify Actually Shows, and Who It's For
- How Tauklarify Compares With the Other Approved Tau Tracer
- How Accurate Is a Tauklarify Scan?
- What the Procedure Involves and Its Safety Profile
- Is It Available Yet, and What to Ask Before Scheduling
- Frequently Asked Questions
What Tauklarify Actually Shows, and Who It's For
Tauklarify is the brand name for florquinitau F-18, also called MK-6240, a radioactive tracer injected before a PET scan. It binds to tau neurofibrillary tangles, the twisted protein threads that build up inside neurons as Alzheimer's progresses, and lets a PET scanner map where they sit in the brain. Lantheus, the manufacturer, received FDA approval for use in adults with cognitive impairment who are already being evaluated for Alzheimer's disease.
That approved population specifically includes people with mild cognitive impairment, the stage where memory or thinking problems are noticeable but do not yet interfere seriously with daily life. The pivotal trials supporting approval enrolled people at this stage, so the imaging agent's cleared use lines up directly with the MCI population comparing testing options, according to Radiology Business. The FDA label is specific about scope: Tauklarify's safety and effectiveness have not been established for tauopathies other than Alzheimer's disease, conditions like frontotemporal dementia that also involve tau buildup but follow a different pattern. A positive scan should be read only within an Alzheimer's workup, not as a general tau test, per Lantheus's release.
How Tauklarify Compares With the Other Approved Tau Tracer
Before Tauklarify, the only FDA-approved tau PET tracer was Eli Lilly's flortaucipir, sold as Tauvid. The European Medicines Agency authorizes Tauvid in the EU for the same kind of cognitive-impairment evaluation, so both tracers now serve an overlapping role on different sides of the Atlantic, according to SNMMI and the EMA's product page.
Having two approved options matters for patients because it opens the door to availability at more imaging centers over time, and gives physicians a choice if one tracer is a better logistical fit for their facility. Neither tracer is described as superior to the other based on the available approval data; the distinction for now is that Tauklarify is simply the newer, second entrant into an otherwise narrow field. For a patient with MCI, the name of the tracer matters less than which one a given imaging center or health system has set up to deliver, since both target the same Alzheimer's-related tau pathology in the same clinical context.
How Accurate Is a Tauklarify Scan?
FDA approval rested on two blinded-read studies, one with 279 subjects and one with 338, comparing how trained readers interpreted the scans against a reference standard for tau pathology. Positive percent agreement — how often the scan correctly flagged true tau buildup — ranged from 80% to 88% in the first study and 68% to 82% in the second.
Negative percent agreement, how often the scan correctly cleared someone without significant tau pathology, ran higher, between 93% and 99% across both studies, according to Healio. In practical terms, the scan is considerably better at ruling tau pathology out than at catching every true case, and the detection rate varied meaningfully between the two studies. That range is worth asking about directly: a scan read as negative is a stronger signal than one read as positive, and a single scan is one data point in a broader workup rather than a stand-alone verdict.
What the Procedure Involves and Its Safety Profile
A Tauklarify scan is an injection followed by a PET scan, similar in structure to other nuclear imaging procedures. Across 1,734 subjects studied before approval, the most common side effects were headache, reported by 0.7% of subjects, nausea at 0.2%, and injection-site reactions at 0.1% — a profile Healio characterized as generally mild, per Healio's coverage.
One detail shapes where the scan can actually be done: Tauklarify is labeled with fluorine-18, an isotope with a half-life of roughly 110 minutes. That short window means each dose has to be manufactured and delivered on a tight schedule, which will likely limit which imaging centers can realistically stock and administer it compared with tracers that have simpler handling requirements, according to Radiology Business. Tauklarify also received FDA fast-track designation before its 2026 approval, an expedited regulatory status reserved for treatments addressing a serious condition with unmet need, according to AuntMinnie.
Is It Available Yet, and What to Ask Before Scheduling
Approval is not the same as access. At the time of the approval announcement, Lantheus had not released a commercial rollout timeline or pricing, and the company said it was still working out the path to wider availability, according to Pharmaceutical Technology.
Patients should not assume a nearby imaging center already offers the scan or that insurance coverage is settled. Given the fluorine-18 handling constraint and the unresolved rollout timeline, a few questions are worth bringing to a neurologist or memory clinic before pursuing a scan: Those answers will determine whether a Tauklarify scan is a realistic option now or something to revisit as Lantheus firms up distribution.
- Does this center currently offer Tauklarify, or only the earlier-approved Tauvid?
- What is the expected wait, given the tracer's 110-minute half-life and delivery scheduling?
- How will the scan result — positive, negative, or in the 68-88% agreement range reported for Tauklarify — actually change the care plan?
- Is the scan covered by insurance, or is pricing still unset at this facility?
Frequently Asked Questions
Is Tauklarify the same as Tauvid?
No. Tauvid (flortaucipir) was the first FDA-approved tau PET tracer; Tauklarify (florquinitau F-18) is a separate, newly approved tracer for the same type of Alzheimer's evaluation.
Can Tauklarify diagnose dementias other than Alzheimer's?
No. The FDA label states its safety and effectiveness are not established for tauopathies outside Alzheimer's disease.
Why might my local imaging center not offer Tauklarify yet?
Lantheus had not announced a rollout timeline or pricing as of the approval, and the tracer's fluorine-18 label, with a roughly 110-minute half-life, limits which centers can handle its tight delivery schedule.
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: How People With Mild Cognitive Impairment Can Compare Testing Options
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How People With Mild Cognitive Impairment Can Compare Testing Options
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: How People With Mild Cognitive Impairment Can Compare Testing Options
